{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-037948","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.273025+00:00","generated_at":"2026-05-31T02:11:42.598098+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroBiologics enters 5-year MSA with Charles River Labs for development and manufacturing services","bullets":["Master Services Agreement with Charles River Laboratories effective September 19, 2024.","Term expires September 19, 2029; services and fees set via future Statements of Work.","Covers development and CDMO services including cell/gene therapy products.","Either party can terminate on 90 days' notice; material breach cure period also 90 days.","Standard confidentiality, IP, warranty, and indemnity terms; financial caps redacted."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-037948","json":"https://secwatch.observer/filing/0001493152-24-037948.json","markdown":"https://secwatch.observer/filing/0001493152-24-037948.md","text":"https://secwatch.observer/filing/0001493152-24-037948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224037948/0001493152-24-037948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224037948/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:11:42.598098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}